The conundrum of online prescription drug promotion: Comment on “trouble spots in online direct-to-consumer prescription drug promotion: A content analysis of FDA warning letters”

Abstract

This commentary discusses pertinent issues from Hyosun Kim’s paper on online prescription drug promotion. The study is well-designed and the findings highlight some of the consequences of the Food and Drug Administration’s (FDA’s) decision to deregulate online advertising of prescription drugs. While Kim’s findings confirm some of the early concerns, they also provide a perspective of implementation challenges in the ever-changing technological environment.